MedTrace Logo

Development of Pharmacogenomic Method to Predict Antidepressant Responsiveness

NCT00817011 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1000

Last updated 2015-12-31

No results posted yet for this study

Summary

The Purpose of this study is to predict antidepressant response in advance using pharmacogenomics and peripheral biological markers in depressed patients.

Conditions

Interventions

DRUG

SSRI treated group

Antidepressant administration of SSRI class for 6 weeks under therapeutic dose

DRUG

non-SSRI treated group

Antidepressant administration of non-SSRI class for 6 weeks under therapeutic dose

Sponsors & Collaborators

  • Samsung Medical Center

    lead OTHER

Principal Investigators

  • Doh Kwan Kim, M.D.,Ph.D. · Samsung Medical Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-04-30
Primary Completion
2016-12-31
Completion
2018-03-31

Countries

  • South Korea

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00817011 on ClinicalTrials.gov